

**CATHEPSIN B: A CONTROVERSIAL TARGET FOR ALZHEIMER'S DISEASE****YADAV M¹ AND AVASTHI A S^{*1}**¹*Amity Institute of Biotechnology, Amity University, Noida, UP, India.***ABSTRACT**

Alzheimer's disease (AD) is an irreversible progressive neurodegenerative disorder, with unresolved etiology and is characterized by the long latency between the initial dysregulation processes and the late appearance of clinical symptoms. It slowly leads to loss in memory, thinking skills, visuospatial orientation, judgement and personality and eventually the person becomes profoundly mute, disabled and immobile. Amyloid beta (A β) generation is the critical initiating event for the development of AD. Cathepsin B (CatB) is an established biomarker for AD. However, its therapeutic role still needs further investigation. Some studies suggest that the CatB act as an anti-amyloidogenic agent via C-terminal degradation of A β peptides, and hence CatB inhibition increases A β levels and plaque deposition. While other studies suggest that CatB inhibition or knockout reduces A β levels and improves memory deficit in AD patients. This review highlights recent studies focussing on the role of CatB in progression or inhibition of AD.

KEY WORDS: *Alzheimer's disease (AD), Cathepsin B (CatB), A β aggregates, anti-amyloidogenic, and Amyloid precursor protein (APP)*

**AVASTHI A S****Amity Institute of Biotechnology, Amity University, Noida, UP, India.*

Received on: 20.12.2016

Revised and Accepted on: 13-03-2017

DOI: <http://dx.doi.org/10.22376/ijpbs.2017.8.2.b369-373>

INTRODUCTION

Alzheimer's disease (AD) is the most common cause of dementia in older persons, with an increasing incidence as a function of age¹. The progression of AD is slow but relentless, with symptoms often progressing to more than 10 years. Initial symptoms are forgetfulness and other memory disturbances; with progression of the disease other symptoms such as specific language impairment (SLI), loss of mathematical skills, and loss of learned motor skills appear. In last stages of AD, affected individuals may become incontinent, mute, and unable to walk. The terminal event is usually an intercurrent disease, often pneumonia. The two pathologic hallmarks of AD, particularly evident in the end stages of the illness, are plaques (A β aggregates) and tangles (tau aggregates). Amyloid beta (A β) generation is the critical initiating event for the development of AD because tau aggregates are formed in other diseases too such as frontotemporal lobar degenerations, progressive supranuclear palsy, and corticobasal degeneration, but A β deposits do not ensue. Also, mutations in the gene for tau do not give rise to AD but rather cause frontotemporal lobar degenerations while mutations in A β give rise to AD. Amyloid precursor protein (APP) is a cell surface protein with a single transmembrane domain that may function as a receptor, possibly for prion protein (PrPc) among other ligands and consists of A β portion of protein that extends from the extracellular region into the transmembrane domain. Processing of APP begins with cleavage in the extracellular domain, followed by an intramembranous cleavage. If APP is first cleaved by α -secretase and then by γ -secretase, a harmless soluble peptide is formed, whereas if APP is first cleaved by β -secretase or β -amyloid-converting enzyme (BACE) and then by γ -secretase, A β peptides are formed, which form pathogenic aggregates and contribute to the characteristic plaques of AD. The variation in peptide length arises from alterations in the exact location of the γ -secretase cleavage, resulting in a C-terminal heterogeneity of the resulting peptide population. Hence, numerous different A β species exist, with A β 40 being the most abundant (~80-90%), followed by A β 42 (~5-10%). The slightly longer forms of A β , particularly A β 42, are more hydrophobic and fibrillogenic, and are the principal species deposited in the brain. Once generated, A β is highly prone to aggregation - first into small oligomers (which may be the toxic form responsible for neuronal dysfunction), and eventually into large aggregates and fibrils.

CATHEPSIN B AND ALZHEIMER'S DISEASE

Cathepsin B (CatB) belongs to the class of cysteine proteases and it degrades peptides and proteins that enter the endolysosomal system through endocytosis or phagocytosis². CatB possesses the unique ability to act both as a dipeptidyl carboxypeptidase and an endopeptidase. However, the carboxyldipeptidic activity of CatB is greater than endopeptidic activity due to presence of 20 residue occluding loop containing 2 histidine residues (His 110 and His 111) on its catalytic site. CatB is encoded by the CTSB gene in humans.

CTSB gene consists of 13 exons and is located on chromosome 22. CTSB gene promoter region contains a GC-rich sequence including many SP1 sites, which is similar to housekeeping gene. CTSB gene has at least five transcript variants encoding same protein. CatB is synthesized as a proenzyme of 339 amino acid with a single peptide of 17 amino acids on the rough endoplasmic reticulum. It is then transported to Golgi apparatus and processed into CatB. Mature CatB is composed of a heavy chain (25-26 kDa) and a light chain (5 kDa), which are linked by disulfide bridge. CatB plays an important role in various diseases such as cancer and AD³⁻⁴. In AD brains, neuronal CatB is present in most early endosomes, internalization and processing site of APP to form A β ⁴⁻⁵. CatB is also associated extracellularly with amyloid plaques. CatB also colocalizes with both A β 40 and A β 42 in regulated secretory vesicles in chromaffin cells⁶. Although CatB is closely associated with intracellular and extracellular A β , the exact function of CatB in APP processing and A β metabolism in central nervous system is still controversial. Some studies suggest that CatB might cleave APP and contribute to A β generation, leading to neuronal deficits in AD⁴⁻⁷. While, some other studies suggest that CatB may catalyse the cleavage of A β peptides, resulting in A β degradation and neuroprotection⁸⁻¹⁴.

ROLE OF CATHEPSIN B IN AMYLOID BETA DEGRADATION: INHIBITOR OF ALZHEIMER'S DISEASE

In 2006, first experimental study supporting the role of CatB in A β degradation was conducted by Mueller-Steiner *et al.*⁸. They showed that CatB effectively cleaved A β 42 peptides resulting in formation of C-terminally truncated A β peptides that are less amyloidogenic. Genetic inactivation of CatB in familial AD hAPP mice model increased A β formation leading to increase in plaque deposition. CatB expression in aged hAPP mice reduced pre-existing A β deposits including thioflavin S-positive plaques. The study showed that CatB possessed anti-amyloidogenic and neuroprotective activities, lack of CatB activity might promote AD and increase in CatB activity could counteract AD neuropathology. In another study conducted by Sun *et al.*, it was found that Cystatin C (CysC) acts as a key inhibitor of CatB-dependent A β degradation *in vivo*⁹. CysC removal is highly effective in promoting CatB-dependent truncation of A β 42, the most pathogenic form of A β peptides in brain. This was evident from the fact that in CysC - deficient mice, levels of A β 42 peptides were found to be lower than in the wild-type mice. In hAPP-J20 mice, CatB inhibition of CysC elevated the relative abundance of A β 42, but this was not evident in CatB deficient mice. Conversely, CatB inhibition in young hAPP-J20 mice elevated the levels of A β 42, but only when CysC levels were reduced. Hence, the study demonstrated that CysC-CatB interaction modulates the relative abundance of A β 42 and CysC inhibits the CatB-induced A β 42 truncation. Therefore, this study showed that CatB inhibitor CysC is a potential target for treating AD and supports the work of Mueller-Steiner *et al.* by demonstrating that CatB causes degradation of A β peptides⁸. In a study conducted by Butler *et al.*, it was

found that low concentration of Z-Phe-Aladiazomethylketone (PADK) results in increase in CatB concentration and increase in A β degradation¹⁰. Hence, selective lysosomal modulation by PADK can be a potential strategy for treatment of AD. In another study conducted by Wang *et al*, it was found that increase in CatB activity lowers A β deposition, especially A β 42 deposition, in AD patients regardless of familial mutations¹¹. Hence, CatB activity enhancement could be a new potential strategy for AD treatment. In recent study of Moon *et al* for determining the factors responsible for cognitive and neurogenic benefits of running, it was found that running increased levels of CatB in gastrocnemius muscle and plasma of mouse and CatB is an important factor for cognitive and neurogenic benefits of running¹². Furthermore, brain-derived neurotrophic factor (BDNF) and doublecortin (DCX) expression enhanced by application of recombinant CTSB gene in adult hippocampal progenitor cells through a mechanism dependent on P11 protein. Also, in CTSB knockout mice, adult hippocampal neurogenesis and spatial memory function were not enhanced by running. Similarly, CatB levels were also found to be elevated in plasma of rhesus monkeys and humans after treadmill exercise. In humans, changes in level of CatB correlated with hippocampus-dependent memory function and fitness. Hence, this study suggested that CatB acts as mediator for cognitive and neurogenic benefits of running, further supporting the findings of Mueller-Steiner *et al* focussing on the positive effect of CatB on brain⁸. In another study conducted by Pait *et al* for studying protein clearing role of lysosomes, it was demonstrated that Z-Phe-Ala-diazomethylketone (PADK; or Z-FA-DMK) positively modulates lysosomal pathway by CatB upregulation, plaques and tangles reduction, and synaptic decline in transgenic mouse models of both, early onset familial AD as well as AD lacking familial mutations¹³. This study indicated that CatB modulators enhance protein clearance mechanisms to promote synaptic markers recovery and reduce multi-proteinopathy. Hence, this study also supports the findings of Mueller-Steiner *et al* (2006) and shows CatB modulators have potential to slow synaptic decline and associated cognitive deficits in AD⁸. In another recent study by Tiribuzi *et al*, it was demonstrated that transcrocetin, a constituent of *Crocus sativus L.*, upregulates CatB leading to enhancement in degradation of A β in AD monocytes¹⁴. CatB inhibitor CA074Me counteracted transcrocetin-induced effect. Hence, transcrocetin can be another potential drug for the treatment of AD. Thus, all the studies cited above suggest that CatB degrades A β peptides, CatB inhibition leads to increase in A β formation and CatB expression in AD reduces the level of pre-existing A β plaques. CysC inhibits CatB-dependent A β truncation and CysC-CatB interaction modulates A β levels. Moreover, lysosomal modulator PADK increases CatB concentration leading to increase in A β degradation. Also, CatB mediates cognitive and neurogenic benefits of running. Furthermore, CatB modulatory compounds enhance protein clearance mechanisms to promote synaptic markers recovery and reduce multi-proteinopathy. Transcrocetin which upregulates CatB was suggested as a potential drug for AD.

ROLE OF CATHEPSIN B IN AMYLOID BETA FORMATION: PROMOTER OF ALZHEIMER'S DISEASE

There have been many reports where CatB has been investigated for its role as a promoter for A β formation ultimately leading to AD. Major source of extracellular A β that is responsible for the A β aggregation in AD is located in secretory vesicles of neurons. Extracellular A β is generated during the β -secretase processing of APP. Previously, the major β -secretase activity was considered to be a cysteine protease. This was proved by a study conducted by Hook *et al.*, in 2005 where they purified the representative cysteine protease and identified it as CatB by peptide sequencing⁶. Colocalization of CatB with A β in these vesicles was demonstrated by immunoelectron microscopy. Cysteine protease inhibitor, CA074Me (cell permeable form of CA074) had no effect on A β secreted by regulated secretory pathway of chromaffin cells but CA074 reduced extracellular A β released by the constitutive pathway. This was the first study demonstrating the role of CatB as β -secretase in regulated secretory pathway of brain neurons and CatB inhibitors as potential drugs to reduce A β load in AD. In another study, Hook *et al* demonstrated that cysteine protease inhibitors CA074Me and E64d effectively reduces memory deficit, A β plaque load, brain A β , and β -secretase activity in London APP mouse model but have no effect in Swedish/London APP mice¹⁵. This difference is due to the expression of wild type (WT) β -secretase site containing APP in London APP mouse, and Swedish mutant (Swe) β -secretase site containing APP in Swedish/London APP mice. This difference was as expected as RSV β -secretase and CatB assays used for compound selection identifies only those compound which inhibits WT β -secretase substrate cleavage and not Swe β -secretase substrate cleavage. Cysteine protease inhibitors may act by inhibiting CatB in London APP mice, thus reducing the A β peptides. Since APP containing WT β -secretase site is expressed in most of the AD patients, efficacy in London APP mouse expressing APP containing WT β -secretase site demonstrates the cysteine protease inhibitors potential as therapeutic agents for AD. Therefore, this study showed that CatB inhibition by cysteine protease inhibitors CA074Me and E64d reduces A β load in AD. In further study, Hook *et al* demonstrated that CTSB gene knockout reduces A β 40 and A β 42 by up to ~67%, reduces CTF β by 41% and increases sAPP α by 61% in mice expressing hAPPwt¹⁶. This shows that CatB has major role in A β peptides formation from hAPPwt in brain. As most AD patients express hAPPwt, this data validates the usage of CatB as potential target for development of inhibitors to reduce A β deposits in AD. Hook *et al* in 2010 also demonstrated the pharmacogenetic differences in effects of CatB inhibitors in different mice models¹⁷. CatB inhibitors were found to have no effect in mice expressing APP containing rare Swe β -secretase site. CatB knockout decreased A β deposits in mice expressing WT APP. Hence, difference in CatB inhibitors responses in different AD mice model is due to the specificity of CatB to cleave WT β -secretase site of APP for A β formation and not the Swe mutant β -secretase site. In contrast, BACE1 β -secretase

cleaves Swe mutant site. BACE1 data do not preclude CatB as also being a β -secretase. It suggests that CatB and BACE1 may jointly act as β -secretases. Significantly, most of AD patients express WT APP and, therefore, CatB inhibitors represent potential drugs for AD. In another study conducted by Sundelof *et al* for CatB levels in plasma and CSF samples in persons with AD, mild cognitive impairment (MCI), and healthy controls, it was found that plasma CatB levels were higher in AD patients compared to healthy controls¹⁸. However, no such significant increase was seen in CatB levels in CSF. No suitable possible mechanism could be provided. This study corroborated the findings of Hook *et al.*^{6,15-17}. Hence, further investigation is needed to confirm the role of CatB as target of AD. Further studies by Hook *et al.*, it was found that E64d (CatB inhibitor) reduced A β deposits, C-terminal β -secretase fragment (CTF β), and CatB activity but increased BACE1 activity in brain of AD guinea pigs and mice models expressing APP containing WT β -secretase site¹⁹. Thus, E64d reduces A β deposits by inhibiting CatB and not BACE1 activity. In another study conducted by Kindy *et al* (2012), it was found that deletion of the CatB gene improves memory deficits in the A β PPWT/Lon AD mouse model expressing human A β PP containing the WT β -secretase site sequence that is present in most AD patients²⁰. However, BACE1 gene knockout had no effect on APPWT/Lon mice. The study supports the findings of Hook *et al* and further provides evidence for the possibility of CatB as drug target for improving memory deficits in most AD patients. Pyroglutamate A β peptides (pGlu-A β) are pernicious forms of A β peptides and are N-terminally truncated forms of full length A β peptides (fA β) in which N-terminal glutamate is cyclized to pyroglutamate. fA β are formed by both β -secretase (BACE1) and CatB cleavage but it is still unknown whether cleavage by BACE1 or CatB can form pGlu-A β . Therefore, Hook *et al* also examined effects of CTSB and BACE1 gene knockout on pGlu-A β levels in transgenic APP/Lon mice containing WT β -secretase activity²¹. CTSB knockout or overexpression reduced or increased, respectively, pGlu-A β and fA β deposits, but BACE1 gene knockout had no effect. CatB inhibitors, E64d and CA074Me, also reduced pGlu-A β and fA β plaque load. Hence, this study illustrates that CatB has a role in pGlu-A β and fA β formation in development of AD. Weber *et al* synthesized monoclonal antibodies against CatB to clarify the role of CatB in neurodegeneration, and it was found that CatB antibodies have 5 different binding sites, thus giving the opportunity to improve detection of CatB by combining CatB specific antibodies in oligoclonal antibody mixtures²². This may result in improved detection of CatB, an established biomarker for AD. In a recent study conducted by Jeon *et al*, it was demonstrated that chalcone derivatives compounds 7 and 11 reduced tau phosphorylation, insoluble A β peptide formation and p25 formation by inhibiting both μ -calpain and CatB enzymes²³. Hence, Chalcone derivatives compounds 7 and 11 can also be a potential drug for treating AD by inhibition of CatB. In another recent study conducted by

Na *et al*, it was proved that A β 42 upregulates CysLT1R and CatB and that CatB is induced by CysLT1R activation²⁴. The study also demonstrated that 6-shogaol, a compound present in ginger, inhibits CysLT1R leading to downregulation of CatB and reduction in A β deposition. Therefore, this study also supports Hook *et al* findings and proves CatB as a potential target for AD and 6-shogaol, a CysLT1R/CatB inhibitor, is a novel potential drug to treat AD. Hence, these studies demonstrate that CatB inhibition and CTSB gene knockout leads to improvement in memory deficits and reduction in fA β and pGlu-A β peptide deposits. Differences in CatB inhibitors effects on different AD mice models are due to specificity of CatB to cleave APP at WT β -secretase site and not on Swe β -secretase site, which are cleaved by BACE1. Hence, CatB is a potential target for AD and CatB inhibitors can prove to become potential drugs for AD treatment.

CONCLUSION

In various studies conducted on AD, CatB has been demonstrated to act as an anti-amyloidogenic agent via C-terminal degradation of A β peptides (including both A β 40 and A β 42). Furthermore, it was also found that CatB inhibition increases A β levels and plaque deposition. CatB cleaved both fibrillar as well as nonfibrillar assemblies of A β peptides into shorter A β peptides that are less pathogenic and amyloidogenic. Moreover, CysC had been suggested to be the main inhibitor of anti-amyloidogenic action of CatB. Also, recent studies conducted in 2016 by various research groups have shown that the CatB levels are increased during running and lead to enhanced hippocampus-dependent memory function. CatB modulators enhance protein clearance mechanisms to promote synaptic markers recovery and thus reduce multi-proteinopathy. Transcrocetin which causes upregulation of CatB may be suggested as a potential drug for AD. In contrast, some other studies suggested that CatB inhibition by gene knockout, chemical inhibitors or RNA silencing can lead to reduction in A β deposits and thus improve memory deficits in AD. Furthermore, it was shown that plasma CatB levels were higher in AD patients as compared to healthy persons. Moreover, recently in 2016, CatB inhibitors Chalcone derivatives compounds 7 and 11 and ginger compound 6-shogaol were also proposed to be potential drugs for treating AD. Based on these data it has been hypothesized that inhibition or knockout of CatB may be a therapeutic strategy in AD. Thus, even in 2016, CatB role in AD is still controversial. It still remains unclear if CatB is promoting or suppressing AD pathogenesis. Hence, further investigation of CatB as a therapeutic protein for AD is warranted.

CONFLICT OF INTEREST

Conflict of interest declared none.

REFERENCES

- Shete RV, Bodhankar SL. *Hemidesmus indicus*: evaluation of its nootropic effect in mice. *Int J Pharm Bio Sci.* 2010; 1(3): 1-10.
- Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. *Annu Rev Physiol.* 1997; 59: 63–88.
- Podgorski I, Sloane BF. Cathepsin B and its role(s) in cancer progression. *Biochem Soc Symp.* 2003; 70: 263-76.
- Cataldo AM, Nixon RA. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. *Proc Natl Acad Sci.* 1990; 87: 3861–65.
- Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased β -amyloidogenesis. *J Neurosci.* 1997; 17: 6142–51.
- Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradzsky KF, Neveu J, Lane W, Hook G, Reisine T. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. *Biol Chem.* 2005; 386(9): 931-40.
- Mackay EA, Ehrhard A, Moniatte M, Guenet C, Tardif C, Tarnus C, Sorokine O, Heintzelmann B, Nay C, Remy JM. A possible role for cathepsins D, E, and B in the processing of β -amyloid precursor protein in Alzheimer's disease. *Eur J Biochem.* 1997; 244: 414–25.
- Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L. Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. *Neuron.* 2006; 51: 703–14.
- Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Wang X, Grubb A, Gan L. Cystatin C–Cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. *Neuron.* 2008; 60(2): 247–57.
- Butler D, Hwang J, Estick C, Nishiyama A, Kumar SS, Baveghems C, Young-Oxendine HB, Wisniewski ML, Charalambides A, Bahr BA. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. *PLoS ONE.* 2011; 6(6): e20501.
- Wang C, Sun B, Zhou Y, Grubb A, Gan L. Cathepsin B degrades amyloid- β in mice expressing wild-type human amyloid precursor protein. *J Bio Chem.* 2012; 287(47): 39834-41.
- Moon HY, Becke A, Berron D, Becker B, Sah N, Benoni G, Janke E, Lubejko ST, Greig NH, Mattison JA, Duzel E, van Praag H. Running-induced systemic cathepsin B secretion is associated with memory function. *Cell Metab.* 2016; 24(2): 332-40.
- Pait MC, Elliott L, Hafner-Ruiz S, Mundell C, Patterson W, Romine H, Ikonne U, Bahr BA. Development of cathepsin B positive modulators to treat multi-proteinopathic dementias: exploiting the lysosomal avenue of protein clearance to promote synaptic recovery. *FASEB J.* 2016; 30(Suppl 707): 1
- Tiribuzi R, Crispolti L, Chiurchiù V, Casella A, Montecchiani C, Del Pino AM, Maccarrone M, Palmerini CA, Caltagirone C, Kawarai T, Orlicchio A, Orlicchio A. Trans-crocetin improves amyloid- β degradation in monocytes from Alzheimer's disease patients. *J Neuro Sci.* 2016; in press.
- Hook V, Kindy M, Hook G. Inhibitors of cathepsin B improve memory and reduce β -amyloid in transgenic Alzheimer's disease mice expressing the wild-type, but not the Swedish mutant, β -secretase site of the amyloid precursor protein. *J Bio Chem.* 2008; 283(12): 7745-53.
- Hook V, Kindy M, Reinheckel T, Peters C, Hook G. Genetic cathepsin B deficiency reduces β -amyloid in transgenic mice expressing human wild-type amyloid precursor protein. *Biochem Biophys Res Commun.* 2009; 386(2): 284-88.
- Hook V, Hook G, Kindy M. Pharmacogenetic features of inhibitors to cathepsin B that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. *Biol Chem.* 2010; 391(8): 861–72.
- Sundelof J, Sundstrom J, Hansson O, Eriksdotter-Jonhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L. Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. *J Alzheimers Dis.* 2010; 22(4): 1223-30.
- Hook G, Hook V, Kindy M. The cysteine protease inhibitor, E64d, reduces brain amyloid- β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β -secretase activity. *J Alzheimers Dis.* 2011; 26(2): 387–08.
- Kindy MS, Yu J, Zhu H, El-Amouri SS, Hook V, Hook GR. Deletion of the cathepsin B gene improves memory deficits in a transgenic Alzheimer's disease mouse model expressing A β PP containing the wild-type β -Secretase site sequence. *J Alzheimers Dis.* 2012; 29(4): 827–40.
- Hook G, Yub J, Toneff T, Kindy M, Hook V. Brain pyroglutamate amyloid-beta is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. *J Alzheimers Dis.* 2014; 41(1): 129–49.
- Weber E, Barbulescu E, Medek R, Reinheckel T, Sameni M, Anbalagan A, Moin K, Sloane BF. Cathepsin B-deficient mice as source of monoclonal anti-cathepsin B antibodies. *Biol Chem.* 2015; 396(3): 277–81.
- Jeon KH, Lee E, Jun KY, Eom JE, Kwak SY, Na Y. Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ -calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble A β peptide formation. *Eu J Med Chem.* 2016; 121: 433–44.
- Na JY, Song K, Lee JW, Kim S, Kwon J. 6-Shogaol has anti-amyloidogenic activity and ameliorates Alzheimer's disease via CysLT1R-mediated inhibition of cathepsin B. *Biochem Biophys Res Commun.* 2016; 477(1): 96-02.

Reviewers of this article

Dr. Navkiran kans, Ph.D.

Assistant Professor, Amity Institute of
Biotechnology, Amity University, Noida,
India



Asst.Prof.Dr. Sujata Bhattacharya

Assistant Professor, School of Biological
and Environmental Sciences, Shoolini
University, Solan (HP)-173212, India



Prof.Dr.K.Suri Prabha

Asst. Editor , International Journal
of Pharma and Bio sciences.



Prof.P.Muthu Prasanna

Managing Editor , International
Journal of Pharma and Bio sciences.

We sincerely thank the above reviewers for peer reviewing the manuscript